New Products Increase Surgical Options in Lumbar Procedures
MEMPHIS, Tenn. - Oct. 23, 2012- Medtronic, Inc. (NYSE: MDT) the world leader in spinal technology announced today key additions to reinforce its posterior degenerative interbody portfolio. These new technologies expand the company's broad innovative offerings for both open and minimally invasive procedural solutions. The launch features the addition of posterior interbody devices that expand, rotate, and articulate. This announcement was made during the 27th annual meeting of the North American Spine Society (NASS) in Dallas.
The interbody portfolio includes the WAVE® platform of products with expandable implants for posterior lumbar interbody fusion surgeries. To broaden the offerings for lumbar interbody fusions, the new portfolio also features a pivoting implant for easier placement as well as a titanium implant that can be inserted and rotated longitudinally. The products are available for sale both in the United States and Europe. The devices come to Medtronic following the acquisition of the German company Advanced Medical Technologies AG (AMT) announced earlier this year.
In an effort to offer a diverse portfolio, the company also announced, the launch of the CAPSTONE CONTROL(TM) Spinal System. With the ability to insert and rotate longitudinally, the CAPSTONE CONTROL(TM) Spinal System provides an interbody device with the potential for less neural retraction when compared to the impacted technique. Risks of this device include possible neurological impairment.
"We have strengthened our industry leading lumbar interbody fusion portfolio that increases surgeon options in treating the unique needs of their patients," said Doug King, senior vice president and president of Medtronic Spinal. "It also provides customers and patients with greater access to established technologies through our sales distribution network, while AMT's strong presence outside the United States further globalizes our business."
Interbody fusion devices areindicated for use with autogenous bone graft and supplemental fixation instrumentation cleared for use in the lumbar spine in patients with Degenerative Disc Disease (DDD) at one or two levels from L2 to S1. These DDD patients may also have up to Grade 1 Spondylolisthesis or retrolisthesis at the involved levels.
The CAPSTONE CONTROL(TM) Spinal System incorporates technology developed by Gary K. Michelson, M.D.
About the Spinal Business at Medtronic The Spinal business, based in Memphis, Tenn., is the global leader in today's spine market and is committed to advancing the treatment of spinal conditions. The Spinal business collaborates with world-renowned surgeons, researchers and innovative partners to offer state-of-the-art products and technologies for orthopaedic and spinal conditions. Medtronic is committed to developing affordable, minimally invasive procedures that provide lifestyle friendly surgical therapies.
About Medtronic Medtronic, Inc. (www.medtronic.com), headquartered in Minneapolis, is the global leader in medical technology - alleviating pain, restoring health, and extending life for millions of people around the world.
Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.
 Mirkovic, SR, Schwartz, DG, and Glazier, KD. 1995. Anatomic Considerations in Lumbar Posterolateral Percutaneous Procedures. Spine 20(18):1965-1971.
Contacts: Victor Rocha Public Relations +1-901-399-2401 Jeff Warren Investor Relations +1-763-505-2696
This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Medtronic, Inc. via Thomson Reuters ONE